| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.13B | +46.3% |
| Gross profit | ¥0.05B | — |
| Operating income | ¥0.02B | — |
| Net income | ¥0.02B | -10.4% |
| Gross margin | 43.3% | Net margin 12.5% |
| Revenue Q/Q | -51.3% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.07B | 56.7% |
| R&D | ¥0.01B | 10.1% |
| SG&A | ¥0.02B | 17.7% |
| Tax & other | ¥0.00B | 0.3% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
光莆股份 ・ 开立医疗 ・ 彩讯股份 ・ 中达安 ・ 同和药业 ・ 扬帆新材 ・ 广和通 ・ 凯普生物 ・ 德艺文创 ・ 正丹股份 ・ 透景生命 ・ 万通智控
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies